Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000150" target="_blank" >RIV/26475821:_____/13:#0000150 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/13:43906481

Výsledek na webu

<a href="http://link.springer.com/article/10.1007/s11239-012-0813-8" target="_blank" >http://link.springer.com/article/10.1007/s11239-012-0813-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11239-012-0813-8" target="_blank" >10.1007/s11239-012-0813-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.

Popis výsledku v původním jazyce

Dual antiplatelet therapy is important treatment modality across the spectrum of coronary artery disease manifestations. However, a significant number of patients do not have a completely effective response to clopidogrel. This study assessed the impactof response after clopidogrel with Verify Now device on prognosis on patients undergoing coronary interventions. Consecutive patients following percutaneous coronary intervention were prospectively enrolled. A loading dose of 600 mg of clopidogrel was administered before or during PCI. Blood samples were drawn within 24 h after clopidogrel administration. The effect of clopidogrel was measured using VerifyNow. All patients were evaluated at 6 months. The primary end-point was the combination of death, MI and stroke. 378 patients (69.3 % men and 30.7 % women) were enrolled. The mean age was 67.2 ? 12.8 years, BMI 28.9 ? 17.7, and 116 patients had diabetes (30.7 %). During the 6-months follow-up 30 patients (7.94 %) experienced a monitore

Název v anglickém jazyce

Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.

Popis výsledku anglicky

Dual antiplatelet therapy is important treatment modality across the spectrum of coronary artery disease manifestations. However, a significant number of patients do not have a completely effective response to clopidogrel. This study assessed the impactof response after clopidogrel with Verify Now device on prognosis on patients undergoing coronary interventions. Consecutive patients following percutaneous coronary intervention were prospectively enrolled. A loading dose of 600 mg of clopidogrel was administered before or during PCI. Blood samples were drawn within 24 h after clopidogrel administration. The effect of clopidogrel was measured using VerifyNow. All patients were evaluated at 6 months. The primary end-point was the combination of death, MI and stroke. 378 patients (69.3 % men and 30.7 % women) were enrolled. The mean age was 67.2 ? 12.8 years, BMI 28.9 ? 17.7, and 116 patients had diabetes (30.7 %). During the 6-months follow-up 30 patients (7.94 %) experienced a monitore

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS9988" target="_blank" >NS9988: Rezistence na protidestičkovou léčbu, její etiologie a možnosti ovlivnění.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

J Thromb Thrombolysis

ISSN

0929-5305

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1-6

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—